
Regulatory flexibility can make continuous improvement possible.
Sally Anliker is the director of regulatory affairs CMC at Eli Lilly and Company
Regulatory flexibility can make continuous improvement possible.
Second in a three-part series that discusses the complexities of QbD implementation in biotech development.
First in a three-part series that discusses the complexities of QbD implementation in biotech product development.
Published: January 1st 2010 | Updated:
Published: December 1st 2009 | Updated:
Published: November 1st 2009 | Updated: